(Q42705514)

5 November 2017

title

Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. (English)

1 reference

5 November 2017

0 references

R Pettipher

1

1 reference

5 November 2017

M G Hunter

2

1 reference

5 November 2017

C M Perkins

3

1 reference

5 November 2017

L P Collins

4

1 reference

5 November 2017

T Lewis

5

1 reference

5 November 2017

M Baillet

6

1 reference

5 November 2017

J Steiner

7

1 reference

5 November 2017

J Bell

8

1 reference

5 November 2017

M A Payton

9

1 reference

5 November 2017

publication date

14 July 2014

1 reference

5 November 2017

1 reference

5 November 2017

volume

69

1 reference

5 November 2017

issue

9

1 reference

5 November 2017

page(s)

1223-1232

1 reference

Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2

5 November 2017

cites work

1 reference

A dominant role for chemoattractant receptor-homologous molecule expressed on T helper type 2 (Th2) cells (CRTH2) in mediating chemotaxis of CRTH2+ CD4+ Th2 lymphocytes in response to mast cell supernatants.

21 January 2018

1 reference

Interaction between prostaglandin D and chemoattractant receptor-homologous molecule expressed on Th2 cells mediates cytokine production by Th2 lymphocytes in response to activated mast cells

21 January 2018

1 reference

Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils

21 January 2018

1 reference

Update on the development of antagonists of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). From lead optimization to clinical proof-of-concept in asthma and allergic rhinitis

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma

21 January 2018

1 reference

Cluster analysis and clinical asthma phenotypes.

21 January 2018

1 reference

Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program

21 January 2018

1 reference

Heterogeneity of airway inflammation in persistent asthma : evidence of neutrophilic inflammation and increased sputum interleukin-8.

21 January 2018

1 reference

Noneosinophilic asthma: a distinct clinical and pathologic phenotype

21 January 2018

1 reference

A large subgroup of mild-to-moderate asthma is persistently noneosinophilic

21 January 2018

1 reference

Mepolizumab and exacerbations of refractory eosinophilic asthma

21 January 2018

1 reference

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

21 January 2018

1 reference

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

21 January 2018

1 reference

Eosinophilic Inflammation in Asthma

21 January 2018

1 reference

Lebrikizumab treatment in adults with asthma

21 January 2018

1 reference

Dupilumab in persistent asthma with elevated eosinophil levels

21 January 2018

1 reference

Reslizumab for Poorly Controlled, Eosinophilic Asthma

21 January 2018

1 reference

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

21 January 2018

1 reference

Prostaglandin D₂ pathway upregulation: relation to asthma severity, control, and TH2 inflammation

21 January 2018

1 reference

Sequence variants of the gene encoding chemoattractant receptor expressed on Th2 cells (CRTH2) are associated with asthma and differentially influence mRNA stability

21 January 2018

1 reference

The single nucleotide polymorphism CRTh2 rs533116 is associated with allergic asthma and increased expression of CRTh2.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/ALL.12451

1 reference

5 November 2017

1 reference